Mylan Recalls Ciprofloxacin Tablets Due to Manufacturing Deviations
Mylan Pharmaceuticals is recalling Ciprofloxacin 500 mg tablets because they were not manufactured according to Good Manufacturing Practices.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which per the rubric corresponds to a score of 4 (Severe) when associated with significant injury or property damage reports, or generally high-risk scenarios where the agency has not downgraded to Class III.
Plain-English summary
Mylan Pharmaceuticals Inc. is recalling Ciprofloxacin Tablets, USP, 500 mg, 100-count bottles (NDC 0378-7098-01). The recall involves 941,270 bottles distributed nationwide and in Puerto Rico.
The recall was initiated because the pharmaceuticals were produced and distributed with active ingredients that were not manufactured according to Good Manufacturing Practices (CGMP Deviations). This classification indicates a potential risk of adverse health consequences, though the source text does not specify reported illnesses or injuries.
Consumers should stop using the recalled medication and contact their healthcare provider or pharmacist for guidance on obtaining a replacement. The specific lot numbers affected are listed in the recall documentation.
The recalled product
- Product
- Ciprofloxacin Tablets, USP, 500 mg,100-count bottles, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A, NDC 0378-7098-01
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Antibiotic
- Affected units
- 941,270
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: 2002732
- 2002733
- 2002734
- 2002735
- 2002736
- 2002737
- 2002738
- 2002739
- 2002740
- 2002741
- 2002742
- 2002743
- 2002744
- 2002745
- 3030000
- 3030001
- 3030002
- 3030003
- 3030004
- 3030005
Distribution
Part of a larger recall action
This product is one of 12 recalled by Mylan Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 12 products in this recall →Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighPrasugrel 5 mg Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-03-26
- CriticalInsulin Glargine Prefilled Pens Recalled for Missing Label
FDA (Drugs) · 2022-08-03
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19